High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Explore this paper's citation graph
Summary
High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
- Type
- article
- Published
- 2003-05-08
- Cited by
- 1,779
- References
- 21
- Access
- Open access
- OpenAlex
- https://openalex.org/W2102591890
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41048909
Keywords
Medicine, Multiple myeloma, Confidence interval, Internal medicine, Hematopoietic stem cell transplantation
References
- Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
- Total therapy with tandem transplants for newly diagnosed multiple myeloma.
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
- Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
- High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
- Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
- Multiple myeloma treated with high dose intravenous melphalan
- Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
- The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma
- Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
- High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
- Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants
- Autologous stem cell transplantation for malignancy: a systematic review of the literature.
- Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
- Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.
- Intensive treatment of multiple myeloma and criteria for complete remission.
- Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
- EVOLVING STRATEGIES FOR THE TREATMENT OF MYELOMATOSIS
- A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Cited by
- Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders.
- Economic Evaluation of a Plerixafor for Stem Cell Mobilization
- Stem cell transplantation for multiple myeloma.
- Toward Personalized Medicine: The potential role of RNA interference in Plasma Cell Dyscrasia
- Tumors of the Osseous Spine
- Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.
- Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
- Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
- MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
- The EORTC QLQ-HDC29: a supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation.
- Serum M‐spike and transplant outcome in patients with multiple myeloma
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
- 153Sm: its use in multiple myeloma and report of a clinical experience
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
- Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT.
- Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
- Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65
- Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
- Multiple myeloma: chemotherapy or transplantation in the era of new drugs
Related papers
- [Conservative therapy for retinoblastoma--effect of melphalan on in vitro electroretinogram].
- Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma
- Factors influencing the chemosensitization of melphalan by misonidazole.
- Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
- Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
- Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
- [Erythroleukemia in multiple myeloma. A case report].
- Novel Therapies in Multiple Myeloma for Newly Diagnosed Non-Transplant Candidates